Chronic congestive heart failure. Chronic combined systolic (congestive) and diastolic (congestive) heart failure
Conditions
Interventions
Intervention 1: Intervention group: They will receive acetazolamide 500 mg tablets in addition to intravenous furosemide on day 0, then 250 mg in addition to oral furosemide on day 2 for two days, and
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Earn at least 8 points from EVEREST score Patients over 18 years old The main clinical sign of volume overload includes edema, ascites confirmed by abdominal ultrasound Pleural effusion confirmed by chest X-ray or chest ultrasound without intravenous furosemide Maintenance treatment with oral furosemide as a loop diuretic =20 mg for at least one month Using SGLT2i drugs including canagliflozin, dapagliflozin, and empagliflozin for at least one month
Exclusion criteria
Exclusion criteria: Systolic blood pressure less than 90 mmHg or mean arterial pressure less than 65 mmHg Estimated glomerular filtration rate (eGFR) <20 ml/min/1.73 m2 Using any diuretic agent except mineralocorticoid receptor antagonists including spironolactone and eplerenone Simultaneous diagnosis of acute coronary syndrome, which is characterized by typical chest pain in addition to an increase in troponin level above the 99th percentile or electrocardiographic changes indicating ischemia or hospitalization as unstable angina.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Random urine sodium to creatinine ratio. Timepoint: The third day of study. Method of measurement: Urine and blood tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| B-type natriuretic peptide. Timepoint: Thirty days of study. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoushang Bavandpour karvane
Tehran University of Medical Sciences
Outcome results
None listed